The present disclosure relates to antigen specific tolerogenic antigen presenting cells presenting antigenic portions of an autoantigen and to related compositions, methods and systems.

Disclosed herein are compositions comprising a chimeric antigen receptor targeting phosphatidylserine on the surface of cancer cells and methods of using the compositions to treat a cancer in a subject.

Disclosed herein are compositions comprising a chimeric fusion protein targeting phosphatidylserine on the surface of hematological cancer cells and methods of using the compositions to treat a hematological cancer in a subject.

The present disclosure relates to combination therapy compositions and methods comprising chimeric Tim receptors, host cells modified to include chimeric Tim receptor molecules, and PARP inhibitors.

Provided herein are engineered T cell receptor (TCR) proteins, nucleic acids, vectors, host cells, methods of treating atherosclerosis-related autoimmune disease, and chimeric antigen receptor expressing T cell (CAR-T) comprising a beta chain CDR3 selected from the amino acid sequence of SEQ ID NOS: 179 to 356 and an alpha chain, wherein the TCR is specific for a human apolipoprotein B (ApoB) epitope, antigen-MHC binding portions, and full-length versions of the same.